MBA Advisors LLC Acquires 57 Shares of Amgen Inc. (NASDAQ:AMGN)

MBA Advisors LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 2.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,909 shares of the medical research company’s stock after purchasing an additional 57 shares during the period. MBA Advisors LLC’s holdings in Amgen were worth $758,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in shares of Amgen during the third quarter worth approximately $25,000. Legacy Investment Solutions LLC bought a new position in Amgen in the third quarter worth approximately $29,000. Heck Capital Advisors LLC purchased a new position in Amgen during the 4th quarter worth $36,000. Livelsberger Financial Advisory bought a new stake in Amgen during the 3rd quarter valued at $56,000. Finally, Icon Wealth Advisors LLC lifted its holdings in shares of Amgen by 3,955.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock worth $56,000 after buying an additional 169,748 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the topic of several research reports. William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Piper Sandler lowered their price target on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. Jefferies Financial Group reissued a “buy” rating and set a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. Bank of America upped their target price on Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a report on Thursday. Finally, Piper Sandler Companies reissued an “overweight” rating and issued a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $313.23.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $293.54 on Monday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96. The firm’s 50 day simple moving average is $272.26 and its 200-day simple moving average is $303.00. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a market capitalization of $157.79 billion, a price-to-earnings ratio of 38.88, a PEG ratio of 3.01 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Analysts expect that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.24%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 119.21%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.